OBJECTIVE： To observe the improvement effects of Danshi Ⅵ granules on the non-alcoholic fatty liver disease in model mice. METHODS： Totally 60 female Kunming mice were randomly divided into normal control group （constant volume of 0.9％ Sodium chloride solution）， model group （constant volume of 0.9％ Sodium chloride solution）， simvastatin group （3 mg/kg） and Danshi Ⅵ granules low-dose， medium-dose and high-dose groups （5.5， 11， 22 g/kg）， with 10 mice in each group. The model group and administration groups received high-fat diet for consecutive 8 weeks to establish non-alcoholic fatty liver disease model. After modeling， they were given relevant medicine intragastrically， once a day， for consecutive 4 weeks. After the last administration the contents of TC， TG， HDL， LDL， and the contents of AST， ALT were determined. Body weight and liver wet weight of mice were weighed， and liver indexes were calculated. Gross morphology and pathological changes of liver tissue in mice were observed， and pathological morphology grading was also performed. SOD activity and MDA content were determined in liver tissue of mice. RESULTS： Compared with normal control group， liver indexes of model group were increased significantly （P＜0.01）； serum contents of TC， TG， LDL， AST and ALT were significantly increased while HDL content was decreased significantly （P＜0.01）. The gross morphology of liver tissue was swollen， gray-white， hard， pinched with granules and greasy feeling， the edge of the round blunt. Pathomorphology showed that the boundary of hepatic lobules was not clear， hepatocytes were swollen， and a large number of spherical lipid droplets appeared in the cytoplasm， which had progressed to the stage of non-alcoholic fatty liver disease. Pathomorphologic score was increased significantly （P＜0.01）. In liver tissue， SOD activity decreased significantly， while HDL content decreased significantly （P＜0.01）. Compared with model group， serum contents of TC were decreased significantly in simvastatin group， Danshi Ⅵ granules low-dose， medium-dose and high-dose groups， while AST and ALT activities were decreased significantly （P＜0.05 or P＜0.01）； the contents of TG and LDL were decreased significantly， while HDL content was increased significantly； liver indexes of simvastatin group and Danshi Ⅵ granules medium-dose and high-dose groups were decreased significantly （P＜0.05）； liver color， texture and morphology tended to normal； pathomorphology improved significantly； the number of steatosis cells was decreased significantly； pathomorphology score was decreased significantly； SOD activity of liver tissue was enhanced significantly while MDA content was decreased significantly （P＜0.01）. CONCLUSIONS： Danshi Ⅵ granules can reduce the degree of non-alcoholic fatty liver disease in high-fat diet-induced model mice， the mechanism of which may be associated with improving lipid metabolism disorder， anti-oxidative stress and lipid peroxidation.